Takeda · Launch Intelligence

Competitor intelligence

Every named rival across the six-asset portfolio, scored on the same readiness model.

Public pipelines & filings · Sep 2026

Tracked rivals

6 assets

Nearest rival launch

9 mo

Rilzabrutinib (Sanofi) vs Mezagitamab

Strongest rival

100

Xywav / Xyrem (Jazz) vs Oveporexton

Avg rival readiness

80/100

portfolio mean

Portfolio position map

x: efficacy Δ vs SoC · y: access readiness · size: rival readiness

Rival distance-to-launch

≤ 6 mo ≤ 12 mo > 12 mo

Head-to-head by asset

Takeda readiness vs each named rival, with efficacy delta vs standard of care.

Oveporexton

Pre-launch

Narcolepsy type 1 · Takeda readiness 78

Full CI page

Rival	Status	Launch in	Readiness	Δ efficacy
Xywav / Xyrem Jazz	Marketed SoC	launched	100-22	0 pts
Pitolisant Harmony	Marketed	launched	92-14	-18 pts
ALKS 2680 Alkermes	Phase 2	34 mo	46+32	+9 pts

Rusfertide

Pre-launch

Polycythemia vera · Takeda readiness 71

Full CI page

Rival	Status	Launch in	Readiness	Δ efficacy
Hydroxyurea Generic SoC	Marketed SoC	launched	100-29	0 pts
Ruxolitinib Incyte	Marketed (2L)	launched	96-25	+12 pts
Givinostat Italfarmaco	Phase 3	22 mo	55+16	+8 pts

Mezagitamab

Pre-launch

Immune thrombocytopenia / IgA nephropathy · Takeda readiness 58

Full CI page

Rival	Status	Launch in	Readiness	Δ efficacy
Niplate / Promacta Amgen / Novartis	Marketed SoC	launched	100-42	0 pts
Fostamatinib Rigel	Marketed	launched	88-30	-6 pts
Rilzabrutinib Sanofi	Filed	9 mo	74-16	+10 pts

Fruzaqla

Launched

Metastatic colorectal cancer (3L+) · Takeda readiness 88

Full CI page

Rival	Status	Launch in	Readiness	Δ efficacy
Lonsurf Taiho / Servier	Marketed SoC	launched	100-12	0 pts
Regorafenib Bayer	Marketed	launched	96-8	-4 pts
Lonsurf + bevacizumab Taiho	Marketed (combo)	launched	90-2	+6 pts

Eohilia

Launched

Eosinophilic esophagitis · Takeda readiness 83

Full CI page

Rival	Status	Launch in	Readiness	Δ efficacy
Dupixent Sanofi / Regeneron	Marketed SoC	launched	100-17	0 pts
Swallowed topical steroids Off-label	Generic	launched	90-7	-22 pts
APT-1011 Ellodi	Phase 3 (revived)	30 mo	40+43	-8 pts

Adzynma

Launched

Congenital thrombotic thrombocytopenic purpura · Takeda readiness 86

Full CI page

Rival	Status	Launch in	Readiness	Δ efficacy
Plasma therapy SoC (blood banks)	Marketed SoC	launched	95-9	0 pts
— No named rival	None disclosed	launched	0+86	0 pts